INMB
Q4 2026 EPS Estimate
$-0.17
Oct 29, 2026 · Reports after close
Revenue Estimate
$2M
FY2029E EPS$0.69
FY2030E EPS$1.81

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
64
Score
6 Buy (67%)2 Hold (22%)1 Sell (11%)
Rating Breakdown
Strong Buy
00%
Buy
667%
Hold
222%
Sell
111%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$22.00
+913.8%
Consensus
$22.00
+913.8%
Bull
$22.00
+913.8%
12-Month Target Range9 analysts
$22.00$22.00$22.00
Current $2.17Consensus
Current Price
$2.17
Upside to Consensus
$19.83

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+7055.02%
EPS
FY2028
Rev+162.69%
EPS
FY2029
Rev+285.29%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$133,333$10M$25M$97M$169M
Low$96,832$7M$18M$70M$122M
High$169,833$12M$32M$123M$215M
EBITDA Avg$-133,333$-10M$-25M$-97M$-169M
Low$-169,833$-12M$-32M$-123M$-215M
High$-96,832$-7M$-18M$-70M$-122M
EBIT Avg$-133,333$-10M$-25M$-97M$-169M
Low$-169,833$-12M$-32M$-123M$-215M
High$-96,832$-7M$-18M$-70M$-122M
Net Income Avg$-23M$-23M$-15M$18M$48M
Low$-27M$-24M$-18M$12M$31M
High$-13M$-22M$-9M$25M$65M
EPS Avg$-0.75$-0.86$-0.50$0.69$1.81
Low$-1.02$-0.90$-0.67$0.44$1.17
High$-0.49$-0.82$-0.33$0.94$2.45
Analysts (Rev / EPS)4 / 23 / 22 / 21 / 11 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$2M$2M$15M
Low$2M$2M$15M
High$2M$2M$15M
EBITDA Avg$-2M$-2M$-15M
Low$-2M$-2M$-15M
High$-2M$-2M$-15M
EBIT Avg$-2M$-2M$-15M
Low$-2M$-2M$-15M
High$-2M$-2M$-15M
Net Income Avg$-6M$-5M$-7M$-3M$-3M$-3M
Low$-6M$-5M$-7M$-3M$-3M$-3M
High$-6M$-5M$-7M$-3M$-3M$-3M
EPS Avg$-0.21$-0.20$-0.24$-0.13$-0.13$-0.13
Low$-0.21$-0.20$-0.24$-0.13$-0.13$-0.13
High$-0.21$-0.20$-0.24$-0.13$-0.13$-0.13
Analysts (Rev / EPS)3 / 13 / 1 / 1 / 1 / 13 / 1

Earnings Surprises

Recent Analyst Actions

Aug 22, 2024Scotiabank
Scotiabank starts INmune with Outperform on Alzheimer's potential
Target:$22.00
+221.2%from $6.85
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.